Progen Pharmaceuticals
Progen Pharmaceuticals

Publications

  1. Parish C.R., Freeman C., Brown K.J., Francis D.J., Cowden W.B. “ Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.” Cancer Research 1999, 59
     
  2. Johnstone KD, Karoli T, Liu L, Dredge K, Copman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E, Chiu FC, Shacklford DM, Charman SA, Charmas WN, Harenberg J, Gonda TJ, Ferro V. Syntheses and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.  J Med Chem.  2010 Feb 25;53 (4): 1686-99
     
  3. Hammond E, li CP, Ferro V. Development of a colorimetric assay for hepranase activity suitable for kinetic analysis and inhibitor screening.  Anal Biochem.  2010 Jan 1;396(1):112-6.  Epub 2009 Sep 11.
     
  4. Kuo WL, Das D, ZiyadS, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, Marton LJ, Gray JW.  A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.  BMC Med.  2009 Dec 14;7:77.
     
  5. Huang Y, Stewart TM, Wu Y, Baylan SB, Marton LJ, Perkins B, Jones RJ, Woster PM, Casero RA Jr. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes.  Clin Cancer Res.  2009 Dec 1;15(23):7217-28.  Epub 2009 Nov 24.
     
  6. Ignatenko NA et al "Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047."  Cancer Genomics Proteomics.  2009 May-Jun;6(3):161-75.
     
  7. Dredge K et al "The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer."  Cancer Chemotherapy and Pharmacology.  2009 DOI 10.1007/s00280-009-1105-7.
     
  8. Dredge K et al "The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and hepranase inhibitors for cancer therapy." Invest New Drugs.  2009 DOI 10.1007/s10637-009-9245-5.
     
  9. Dredge K, Kink JA, Johnson RM, Bytheway I, Marton LJ. “The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.” Cancer Chemotherapy and Pharmacology. 2009 August 18 [Epub ahead of print] DOI 10.1007/s00280-009-1105-7.
     
  10. Hudachek SF, Eckhardt SG, Hicks B, Gustafson DL. Population pharmacokinetic model of PI-88, a heparanase inhibitor. Cancer Chemother Pharmacol. 2009 Jul 25. [Epub ahead of print]. DOI 10.1007/s00280-009-1080-z
     
  11. Ignatenko NA, Yerushalmi HF, Pandey R, Kachel KL, Stringer DE, Marton LJ, Gerner EW. “Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047.” Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.
     
  12. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ. “Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.” J Hepatol. 2009 May;50(5):958-68. Epub 2009 Feb 15.
     
  13. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, Handley P, Wimmer N, Gonda TJ, Gautam A, Ferro V, Bytheway I. “The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.” Invest New Drugs. 2009 Apr 9. [Epub ahead of print] DOI 10.1007/s10637-009-9245-5.
     
  14. Cochran S, Li CP, Ferro V. “A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins.” Glycoconj J. 2009 Jul;26(5):577-87. Epub 2008 Nov 26.
     
  15. Liu L, Bytheway I, Karoli T, Fairweather JK, Cochran S, Li C, Ferro V. “Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides.” Bioorg Med Chem Lett. 2008 Jan 1;18(1):344-9. Epub 2007 Oct 25.
     
  16. Fairweather JK, Hammond E, Johnstone KD, Ferro V. “Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88.” Bioorg Med Chem. 2008 Jan 15;16(2):699-709. Epub 2007 Oct 18.
     
  17. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, Johnstone K, Karoli T, Davis K, Copeman E, Gautam A. “PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.” Semin Thromb Hemost. 2007 Jul;33(5):557-68.
     
  18. Casero RA Jr, Marton LJ. “Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases.” Nature Review Drug Discovery 2007 May;6(5):373-90.
      
  19. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA Jr.  “Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes”. Proc Natl Acad Science U S A. 2007 May 8;104(19):8023-8. Epub 2007 Apr 26
     
  20. Basche M., Gustafson D.L., Holden S.N., O'Bryant C.L., Gore L., Witta S., Schultz M.K., Morrow M., Levin A., Creese B.R., Kangas M., Roberts K., Nguyen T., Davis K., Addison R.S., Moore J.C. and Eckhardt G. “A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advance solid tumors.” Clinical Cancer Research 2006,12(18), 5471-5480
     
  21. Joyce J.A., Freeman C., Meyer-Morse N., Parish C.R. & Hanahan D. "A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.” Oncogene 2005, Jun 9;24 (25): 4037-51. Erratum in: Oncogene, Jun 9;24 (25): 4163.
     
  22. Ferro V., Hammond E. & Fairweather J.K. “The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation.” Mini Reviews in Medicinal Chemistry 2004, 4, 693-702.
     
  23. Hulett M.D., Freeman C., Hamdorf B. J., Baker R. T., Harris M. J. & Parish C. R. “Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.” Nature Medicine 1999, 5, 803-809. , 3433-3441    
CONTACT US | CAREERS | SEARCH | SITE MAP | DISCLAIMER | PRIVACY
Home Our Company Our Technology Our Pipeline Investor Centre